ArticleIntegrative medicine research2026
Ameliorative effects of Wiryeongtang (herbal medicine) on cardiorenal complications via modulation of inflammatory and fibrotic responses in diabetic mice.
Article in Integrative medicine research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetes causes cardiorenal complications characterized by inflammation, fibrosis, and metabolic dysfunction. Wiryeongtang (WRT), a traditional herbal formula, has shown potential in alleviating metabolic disorder-related complications. This study aimed to investigate the protective effects of WRT on cardiorenal complications in diabetic mice. Methods: Four groups were studied: a non-diabetic control (db/m), an untreated diabetic group (db/db), a vildagliptin-treated group (50 mg/kg/day) as a positive control, and a WRT-treated group (200 mg/kg/day). Metabolic parameters, including plasma blood glucose, lipid accumulation, and oral glucose tolerance, were measured. Renal histology was assessed for glomerulosclerosis, mesangial matrix expansion, and fibrosis. Cardiac tissues were examined for hypertrophy, fibrosis, and inflammation. Apoptotic markers (caspase-3, caspase-9, Bcl-2, and Bax) were also measured. Results: WRT significantly reduced plasma blood glucose levels and lipid accumulation in db/db mice and improved oral glucose tolerance and insulin resistance. WRT reduced glomerulosclerosis, mesangial matrix expansion, and fibrosis markers in the kidneys. WRT also mitigated diabetes-induced cardiac dysfunction and histopathological changes, including hypertrophy, fibrosis, and inflammation. Additionally, WRT downregulated apoptotic markers (caspase-3 and caspase-9) while increasing the Bcl-2/Bax ratio. Conclusions: The findings suggest that WRT may serve as a potential therapeutic agent for managing cardiorenal complications associated with type 2 diabetes. It alleviated hyperglycemia, improved insulin sensitivity, and reduced inflammation and fibrosis in both cardiac and renal tissues through anti-apoptotic and anti-fibrotic mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.